{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T17:10:30Z","timestamp":1771953030022,"version":"3.50.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2004,9,1]],"date-time":"2004-09-01T00:00:00Z","timestamp":1093996800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2004,9]]},"DOI":"10.1007\/s10557-005-5059-7","type":"journal-article","created":{"date-parts":[[2005,2,16]],"date-time":"2005-02-16T20:46:00Z","timestamp":1108586760000},"page":"353-362","source":"Crossref","is-referenced-by-count":22,"title":["Cardioprotective Action of Perindopril versus Candesartan in Renovascular Hypertensive Rats"],"prefix":"10.1007","volume":"18","author":[{"given":"Makoto","family":"Nagai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuaki","family":"Horikoshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takehiko","family":"Izumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shingo","family":"Seki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayuki","family":"Taniguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ikuo","family":"Taniguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seibu","family":"Mochizuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"issue":"part2","key":"5059_CR1","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1161\/01.HYP.37.2.342","volume":"37","author":"H Gavras","year":"2001","unstructured":"Gavras H, Brunner HR. Role of angiotensin and its inhibition in hypertension, ischemic heart disease, and heart failure. Hypertens 2001;37(part2):342\u2013345.","journal-title":"Hypertens"},{"key":"5059_CR2","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S0140-6736(00)02213-3","volume":"355","author":"B Pitt","year":"2000","unstructured":"Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: Randomised trial\u2014The Losartan Heart Failure Survival Study ELITE II. Lancet 2000;355:1582\u20131587.","journal-title":"Lancet"},{"key":"5059_CR3","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S0735-1097(01)01775-2","volume":"39","author":"P Jong","year":"2002","unstructured":"Jong P, Demers C, McKelvie RS, Liu PP. Angiotensin receptor blockers in heart failure: Meta-analysis of randomized controlled trials. J Am Coll Cardiol 2002;39:463\u2013470.","journal-title":"J Am Coll Cardiol"},{"key":"5059_CR4","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1006\/jmcc.2002.2075","volume":"34","author":"J Varagic","year":"2002","unstructured":"Varagic J, Frohlich ED. Local cardiac renin-angiotensin system: Hypertension and cardiac failure. J Mol Cell Cardiol 2002;34:1435\u20131442.","journal-title":"J Mol Cell Cardiol"},{"key":"5059_CR5","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1161\/01.HYP.35.6.1183","volume":"35","author":"WCD Mello","year":"2000","unstructured":"Mello WCD, Danser AHJ. Angiotensin II and the heart on the intracrine renin-angiotensin system. Hypertens 2000;35:1183\u20131188.","journal-title":"Hypertens"},{"issue":"part1","key":"5059_CR6","doi-asserted-by":"crossref","first-page":"22S","DOI":"10.1016\/S0895-7061(01)02275-0","volume":"15","author":"B Pitt","year":"2002","unstructured":"Pitt B. Clinical trials of angiotensin receptor blockers in heart failure: What do we know and what will we learn? Am J Hypertens 2002;15:(part1):22S\u201327S.","journal-title":"Am J Hypertens"},{"issue":"suppl","key":"5059_CR7","first-page":"S95","volume":"14","author":"T Unger","year":"1996","unstructured":"Unger T, Chung O, Csikos T, et al. Angiotensin receptors. J Hypertens 1996;14(suppl):S95\u2013S103.","journal-title":"J Hypertens"},{"key":"5059_CR8","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/sj.jhh.1001184","volume":"15","author":"BS Chin","year":"2001","unstructured":"Chin BS, Lip GY. Blockade of the renin-angiotensin-aldosterone system with combination angiotensin receptor antagonist and ACE inhibitor therapy: Observations from Val-HeFT and CALM. J Hum Hypertens 2001;15:89\u201392.","journal-title":"J Hum Hypertens"},{"key":"5059_CR9","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1023\/A:1026215712983","volume":"17","author":"F Simko","year":"2003","unstructured":"Simko F, Simko J, Fabryova M. ACE-inhibition and angiotensin II receptor blockers in chronic heart failure: Pathophysiological consideration of the unresolved battle. Cardiovasc Drug Ther2003;17:287\u2013290.","journal-title":"Cardiovasc Drug Ther"},{"key":"5059_CR10","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1161\/01.CIR.97.19.1952","volume":"97","author":"K Harada","year":"1998","unstructured":"Harada K, Komuro I, Shiojima I, et al. Pressure overload induces cardiac hypertrophy in angiotensin II type 1A receptor knockout mice. Circulation 1998;97:1952\u20131959.","journal-title":"Circulation"},{"key":"5059_CR11","first-page":"H1824","volume":"273","author":"M Obayashi","year":"1997","unstructured":"Obayashi M, Yano M, Kohno M, et al. Dose-dependent effect of ANG II-receptor antagonist on myocyte remodeling in rat cardiac hypertrophy. Am J Physiol 1997;273:H1824\u20131831.","journal-title":"Am J Physiol"},{"key":"5059_CR12","first-page":"1163","volume":"12","author":"JB O\u2019Sulliivan","year":"1994","unstructured":"O\u2019Sulliivan JB, Black MJ, Bertram JF, Bobik A. Cardiovascular hypertrophy in one-kidney, one clip renal hypertensive rats: A role for angiotensin II? J Hypertens 1994;12:1163\u20131170.","journal-title":"J Hypertens"},{"key":"5059_CR13","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1097\/00005344-200004000-00009","volume":"35","author":"T Higashi","year":"2000","unstructured":"Higashi T, Kobayashi N, Hara K, Shirataki H, Matsuoka H. Effects of angiotensin II type 1 receptor antagonist on nitric oxide synthase expression and myocardial remodeling in Goldblatt hypertensive rats. J Cardiovasc Pharmacol 2000;35:564\u2013571.","journal-title":"J Cardiovasc Pharmacol"},{"key":"5059_CR14","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1161\/hy0202.103417","volume":"39","author":"JL Zhuo","year":"2002","unstructured":"Zhuo JL, Mendelsohn FA, Ohishi M. Perindopril alters vascular angiotensin-converting enzyme, AT1 receptor, and nitric oxide synthase expression in patients with coronary heart disease. Hypertens 2002;39:634\u2013638.","journal-title":"Hypertens"},{"key":"5059_CR15","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/0006-291X(89)91657-4","volume":"160","author":"K Fukui","year":"1989","unstructured":"Fukui K, Iwao H, Nakamura A, et al. Captopril and hydralazine suppress atrial natriuretic peptide (ANP) gene expression in the ventricles of spontaneously hypertensive rat. Biochem Biophys Res Commun 1989;160:310\u2013316.","journal-title":"Biochem Biophys Res Commun"},{"key":"5059_CR16","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1097\/00004872-199609000-00012","volume":"14","author":"GRD Dussaillant","year":"1996","unstructured":"Dussaillant GRD, Gonzalez H, Cespedes C, Jalil JE. Regression of left ventricular hypertrophy in experimental renovascular hypertension: Diastolic dysfunction depends more on myocardial collagen than it does on myocardial mass. J Hypertens 1996;14:1117\u20131123.","journal-title":"J Hypertens"},{"key":"5059_CR17","first-page":"758","volume":"31","author":"W Zierhut","year":"1996","unstructured":"Zierhut W, Studer R, Laurent DK, et al. Left ventricular wall stress and sarcoplasmic reticulum Ca2+-ATPase gene expression in renal hypertensive rats: Dose-dependent effects of ACE inhibition and AT1-receptor blockade. Cardiovasc Res 1996;31:758\u2013768.","journal-title":"Cardiovasc Res"},{"key":"5059_CR18","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1161\/01.HYP.26.1.101","volume":"26","author":"A Nicoletti","year":"1995","unstructured":"Nicoletti A, Heudes D, Hinglais N, et al. Left ventricular fibrosis in renovascular hypertensive rats. Effect of losartan and spironolactone. Hypertens 1995;26:101\u2013111.","journal-title":"Hypertens"},{"key":"5059_CR19","doi-asserted-by":"crossref","first-page":"3164","DOI":"10.1161\/01.CIR.96.9.3164","volume":"96","author":"W Linz","year":"1997","unstructured":"Linz W, Jessen T, Becker RHA, Scholkens BA, Wiemer G. Long-term ACE inhibition doubles lifespan of hypertensive rats. Circulation 1997;96:3164\u20133172.","journal-title":"Circulation"},{"key":"5059_CR20","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1161\/01.CIR.83.6.1849","volume":"83","author":"KT Weber","year":"1991","unstructured":"Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation 1991;83:1849\u20131865.","journal-title":"Circulation"},{"key":"5059_CR21","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1139\/y97-163","volume":"75","author":"LS Matsubara","year":"1997","unstructured":"Matsubara LS, Matsubara BB, Okoshi MP, Franco M, Cicogna AC. Myocardial fibrosis rather than hypertrophy induces diastolic dysfunction in renovascular hypertensive rats. Can J Physiol Pharmacol 1997;75:1328\u20131334.","journal-title":"Can J Physiol Pharmacol"},{"key":"5059_CR22","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1161\/01.HYP.26.6.971","volume":"26","author":"V Robert","year":"1995","unstructured":"Robert V, Silvestre JS, Charlemagne D, et al. Biological determinants of aldosterone-induced cardiac fibrosis in rats. Hypertens 1995;26:971\u2013978.","journal-title":"Hypertens"},{"key":"5059_CR23","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1006\/jmcc.1999.0963","volume":"31","author":"SH Slight","year":"1999","unstructured":"Slight SH, Joseph J, Ganjam VK, Weber KT. Extra-adrenal mineralocorticoids and cardiovascular tissue. J Mol Cell Cardiol 1999;31:1175\u20131184.","journal-title":"J Mol Cell Cardiol"},{"key":"5059_CR24","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt B, Zannard F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709\u2013717.","journal-title":"N Engl J Med"},{"key":"5059_CR25","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1530\/acta.0.1220369","volume":"122","author":"H Sasamura","year":"1990","unstructured":"Sasamura H, Suzuki H, Kato R, Saruta T. Effects of angiotensin II, ACTH, and KCl on the adrenal renin-angiotensin system in the rat. Acta Endocrinol (Copenh) 1990;122:369\u2013373.","journal-title":"Acta Endocrinol (Copenh)"},{"key":"5059_CR26","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/S0140-6736(01)06300-0","volume":"358","author":"B Zuraw","year":"2001","unstructured":"Zuraw B. Bradykinin in protection against left-ventricular hypertrophy. Lancet 2001;358:1116\u20131118.","journal-title":"Lancet"},{"key":"5059_CR27","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1161\/hc0502.102965","volume":"105","author":"ME Marin-Casta\u00f1o","year":"2002","unstructured":"Marin-Casta\u00f1o ME, Schanstra JP, Neau E, et al. Induction of functional bradykinin B1-receptors in normotensive rats and mice under chronic angiotensin-converting enzyme inhibitor treatment. Circulation 2002;105:627\u2013632.","journal-title":"Circulation"},{"key":"5059_CR28","doi-asserted-by":"crossref","unstructured":"The ALLHAT Officers and Coordinators for ALLHAT Collaborative Research Group. Major Outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288:2981\u20132997.","DOI":"10.1001\/jama.288.23.2981"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-005-5059-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10557-005-5059-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-005-5059-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T17:27:55Z","timestamp":1559237275000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10557-005-5059-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,9]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2004,9]]}},"alternative-id":["5059"],"URL":"https:\/\/doi.org\/10.1007\/s10557-005-5059-7","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,9]]}}}